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a b s t r a c t
We present a case of a mother and daughter who were initially diagnosed with polycythaemia vera and
treated with venesectio. As JAK2 V6217F/exon 12 mutation analyses became available, these were
performed and turned out negative. Haemoglobin electrophoresis was performed and the patients were
found to have high oxygen afﬁnity haemoglobin Ypsilanti. It is important and relevant to look for high
oxygen afﬁnity variants of haemoglobin when there is a family history of erythrocytosis, in young
persons and when there is no apparent reason or clonal marker present.
& 2013 The Authors. Published by Elsevier Ltd.
1. Introduction
Haemoglobin Ypsilanti is a rare high oxygen afﬁnity haemoglo-
bin variant. The haemoglobinopathia is inherited autosomally
dominant and most affected individuals are heterozygote. Due to
the high oxygen afﬁnity of the haemoglobin (Hb) molecule, hypoxia
arises in the tissues, and secondary erythrocytosis develops [1].
More than 900 structural haemoglobin variants have been
described. Of these more than 100 show high oxygen afﬁnity [2].
Erythrocytosis caused by Hb Ypsilanti was ﬁrst described in 1967
[3], and the mutation results in substitution of amino acid (β99
Asp-Tyr) involved in the stability of the quaternary structure of
the haemoglobin tetramer [2,4]. Hb Ypsilanti is unusual, because
the tetramer of the liganded form of Hb Ypsilanti is more stable
than the deoxy tetramer. Hb Ypsilanti also exhibits large quatern-
ary enhancement effect, where the binding of all 4 ligands is
greater than for the isolated α1β1 dimers [4].
Since 2008, diagnostic make-up of patients presenting with
polycythaemia includes examination for the JAK2 V6217F/exon 12
mutations [5]. The JAK2 V617F mutation is present in more than 95%
of patients with polycythaemia vera (PV) and in the small group of
patients without this clonal marker a variant mutation in exon 12 is
almost always found [6]. Furthermore endogenous erythroid colony
(EEC) formation in vitro may be a criterion of PV [5].
We report two patients with high oxygen afﬁnity Hb and
highlight the importance of differential diagnoses in erytrocytosis.
2. Cases
In 2003 a 51-year-old woman (patient 1) was referred due
to a B-Hb up to 21 g/dl and a haematocrit of 0.67. The patient
presented with symptoms of a (transient) cerebral ischaemic
attack. Magnetic resonance imaging of the cerebrum showed no
apoplexy but hydrocephalus. The patient was later treated with a
ventriculo-peritoneal shunt.
The patient suffered from hypertension and had been smoking
about 20 cigarettes daily for her entire adult life. She had
experienced a pressing sensation in the head, had difﬁculty
concentrating and was chronically tired. As long as she could
remember, she had had elevated B-Hb.
In 2007 her daughter, a 24-year-old woman, (patient 2), was
referred for evaluation due to headaches for 3 weeks and an
elevated B-Hb (16 g/dl).
Both patients were considered as atypical PV (Table 1). From
the time of diagnosis the patients have been treated with vene-
sectio, when the haematocrit was above 0.42, or the patient
experienced symptoms such as itching and sweating – and almost
always followed by a subjective relief and beneﬁt. Patient 1 also
received acetylsalicylate 75 mg daily and later marcoumar after
multiple pulmonary embolisms due to immobilisation after sur-
gery. Patient 2 had no thromboembolic complications. She has
received acetylsalicylate prophylaxis, and had two uneventful
pregnancies and deliveries.
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In 2008 and 2010 the JAK2 V617F and exon 12 mutation
analyses were performed, and showed a wild type status in both
patients. EEC was found normal by in vitro analysis (Table 1).
Since patient 1 was young, there was a family history, and no
clonality was found, other causes for erythrocytosis than PV were
considered. In 2012 separation of haemoglobins was performed
revealing the haemoglobin variant Hb Ypsilanti.
Three other family members have been tested for erythrocy-
tosis, which was not observed (Fig. 1). Further follow-up is not
possible due to lack of contact, death or very young age. The two
children of patient 2 have not had haemoglobin measured at birth.
Besides, for patient 1 thrombosis have occurred in at least 2 other
family members and one has been treated with anticoagulants
(cause unknown) (Fig. 1). In both patients reported here we have
reduced the venesectio frequency, allowing a B-Hb higher in the
normal range.
3. Methods
Haemoglobin fractions were obtained by liquid chromatography
on a Waters UPLC (Waters, Milford, MA, USA) by using a Cation-
exchange PolyCat column (354.6 mm, 3 mm, 1500 Å) (PolyLC Inc.,
Columbia, MD, USA). Genomic DNA was puriﬁed from leucocytes
using the QIAamp DNA Blood Mini QIAcube Kit (Qiagen, Hilden,
Germany) according to the manufacturer′s instructions. Part of the
β-globin gene was ampliﬁed using the forward primer A (5′–ATA
TCT TAG AGG GAG GGC–3′) and the reverse primer B (5′–CCC ATT
CTA AAC TGT ACC–3′). PlatinumsTaq DNA Polymerase (Invitrogen,
Carlsbad, CA, USA) was used according to the manufacturer’s
instructions for polymerase chain reaction (PCR) ampliﬁcation.
The following conditions were used: denaturation for 120 s at
95 1C, 32 cycles of 30 s at 9 1C, 40 s at 60 1C and 60 s at 72 1C
followed by a ﬁnal elongation of 7 min at 72 1C. The PCR product
was puriﬁed using QIAquick (Qiagen) PCR puriﬁcation kit according
to the manufacturer’s instructions. Sequencing was performed
using the BigDyes Terminator v3.1 Cycle Sequencing Kit (Applied
Biosystems, Carlsbad, CA, USA) and subsequently puriﬁed using the
BigDyes XTerminator puriﬁcation kit according to the manufac-
turer′s instructions. Primers for sequencing were primers A and B.
Sequencing was performed on an Applied Biosystems 3500 Genetic
Analyser (Life Technologies, Carlsbad, CA, USA).
In vitro test for EEC, JAK2 mutations and paraclinical para-
meters were performed by routine analysis.
4. Discussion
It is always important to make the correct diagnosis – in
particular when molecular biological analyses are available. The
pursuit of the correct diagnosis was intensiﬁed in these patients
when signs of clonality were not demonstrated. Since there was a
family history with erythrocytosis, and furthermore, because
patient 2 was young to develop PV, other reasons for polycythae-
mia were considered. The inheritance in myeloproliferative dis-
orders is complex and difﬁcult to evaluate in a single family (Fig. 1)
[7]. Hereditary erythrocytosis can be associated with mutations in
the gene encoding the erythropoietin receptor, defects in the
oxygen sensing pathways and abnormal oxygen delivery [8].
Calculation of P50 may be indicative of abnormal oxygen delivery
Table 1
Manifestations and analysis at diagnosis and later in the course (year).
Parameter (normal range) Patient 1 Patient 2
Age at diagnose 51 years 24 years
Comorbidity Hypertension, hydrocephalus None
Symptoms at diagnose TCI, fatigue, pressing sensation in the head, difﬁculty
concentrating
Headache for 3 weeks
Haemoglobin (11.3–16.1 g/dL) 21 (2003) 16 (2007)
Haematocrit 0.67 (2003) 0.56 (2007)
MCV (80–100 fL) n.a. 81 (2007)
MCHC (19–22 mmol/L) n.a. 20.1 (2007)
White blood cells (3–9 billions/L) 7.0 (2003) 7.0 (2007)
Platelets (150–400 billions/L) 235 (2003) 179 (2007)
Iron (10–35 μmol/L) 4 (2007) 7 (2007)
Ferritin (12–300 μg/L) 6 (2007) 5 (2007)
Reticulocytes (25–99 billions/L) 113 (2006) 56 (2007)
Cobalamin (145–640 pmol/L) 569 (2007) 349 (2007)
Homocystein (4–15 μmol/L) 11.0 (2007) 11.3 (2007)
Methylmalonat (o0.28 μmol/L) 0.17 (2007) 0.20 (2007)
Erythropoietin (5–30 IU/L) 23 (2003) 118 (2010) 8.9 (2007)
Bone marrow biopsy Found in concordance with a chronically
myeloprolifetive disorder (hypercellularity, domination
of erythropoiesis, but also numerous partly
hyperlobular megakaryocytes scattered in the
reticulum, mild eosinophilia, a myelopoiesis that was
well represented and with normal maturation. No iron
deposits)
Showed hypercellularity with slight left shift, no sign
of malignancy. Iron deposits scarce.
Normal cytogenetics, normal HUMARA test
X-inactivation pattern (25:75)
Peripheral blood smear Normal (2003) Normal (2009)
JAK 2 V617F exon 12 mutation Negative (JAK 2 V617F – 2008 and exon 12 – 2010) Negative (JAK 2 V617F – 2007 and exon 12 – 2010)
Abdominal ultrasound Normal in 2003, in 2009 splenomegaly with longest
diameter 13.7 cm.
Normal (2007)
Chest X-ray Normal (2003) Normal (2007)
PCR for BCR-abl transcript n.a. Negative (2007)
Endogenous Erythroid Colony
formation in vitro
Normal (2012) Normal (2009)
CFU-GM colony growth n.a. Normal (2009)
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in patients with erythrocytosis [8]. If a low value is found the next
step would be sequencing of the globin genes. In the patients
reported here P50 was not calculated, speciﬁcally due to marcou-
mar anticoagulation therapy in patient 1. Alternatively, the speciﬁc
diagnostic analyses were performed.
The therapeutic strategy in PV and high afﬁnity oxygen states is
very different. The strict venesectio activity and reduction of
haematocrit to 0.45 or below is not rational in a patient with a
high afﬁnity haemogloinopathia. Furthermore no cytoreductive
therapy is necessary in haemoglobinopathy. The introduction of
hydroxyurea or interferon-alpha therapy may induce side effects
and in principle a risk for long-term complications. The risk of
transformation to leukaemia in clonal erythrocytosis is not present
in a haemoglobinopathia, and this fact has a signiﬁcant positive
psychological impact. However, the risk to transfer a hereditary
disease may be just as difﬁcult to acknowledge and handle.
A review of the literature and reported cases show that
erythrocytosis due to high oxygen afﬁnity haemoglobin is usually
well tolerated in younger patients, but in the elderly patients the
risk of thrombosis is increased [1]. The development of pulmonary
embolism in patient 1 seems to be secondary to other causes.
Treatment strategy in high afﬁnity hemoglobinopathia should be
decided individually [1,2].
It is important and relevant to look for high oxygen afﬁnity variants
of haemoglobin when there is a family history of erythrocytosis, in
young persons and when there is no apparent reason or clonal marker
present.
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Fig. 1. Family pedigree in haemoglobinopathia Ypsilanti.
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